Soliris TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: eculizumab
Pack: Soliris 300 mg/30 mL injection, 30 mL vial
Brand name
(ARTG)
: SOLIRIS eculizumab (rmc) 300 mg/30 mL concentrated solution for intravenous infusion vialDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
SOLIRIS is indicated for the treatment of patients with: Paroxysmal Nocturnal Haemoglobinuria (PNH) to reduce haemolysis. atypical Haemolytic Uraemic Syndrome (aHUS). Adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. Soliris is not intended for acute treatment of a NMOSD relapse.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, intravenous infusion
- Intravenous Infusion
- 30 mL of clear colourless liquid contained in a labelled, 30 mL glass vial
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Do not Shake
- Shelf lifetime is 30 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 x 30 mL vial pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient eculizumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems